Trial · NCT06893380
Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer
NCT06893380, Recruiting, CHA University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer. Trials, record NCT06893380. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06893380
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer
- NCT number
- NCT06893380
- Status
- Recruiting
- Enrollment
- 61 participants, estimated
- Lead sponsor
- CHA University
- Conditions
- Locally Advanced Biliary Tract Cancers, Metastatic Biliary Tract Cancers
- Interventions
- Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab.
- First posted
- 2025-03-25
- Last updated
- 2025-09-15
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | Up to 24 months after treatment initiation. | The proportion of patients who achieve a complete response (CR) or partial response (PR) according to RECIST v1.1. |
| Secondary | Overall Survival (OS) | Up to 36 months after treatment initiation. | Time from the date of first dose to the date of death from any cause. |
| Secondary | Progression-Free Survival (PFS) | Up to 24 months after treatment initiation. | Time from the date of first dose to disease progression per RECIST v1.1 or death from any cause. |
| Secondary | Disease Control Rate (DCR) | Up to 24 months after treatment initiation. | The proportion of patients who achieve complete response (CR), partial response (PR), or stable disease (SD) per RECIST v1.1. |
| Secondary | Duration of Response (DOR) | Up to 24 months after treatment initiation. | Time from first documented response (CR or PR) to progression or death. |
| Secondary | Quality of Life (QoL)- EORTC QLQ-C30 | Up to 24 months after treatment initiation. | Patient-reported quality of life assessed using the EORTC QLQ-C30 questionnaire. |
| Secondary | Quality of Life (QoL)- EORTC QLQ-BIL21 | Up to 24 months after treatment initiation. | Patient-reported quality of life assessed using the EORTC QLQ-BIL21 questionnaire. |
| Secondary | Safety and Tolerability | Up to 30 days after last dose. | Incidence, severity, and type of adverse events (AEs), graded per NCI CTCAE v5.0. |
| Other | Immune System Response and Immunomodulation Markers | Baseline, during treatment (every 3 cycles; each cycle = 21 days), and at progression (up to 24 months) | Changes in immune system markers in peripheral blood and tumor tissue samples, including: CD8+ T-cell count (%) PD-L1 expression levels in tumor tissues Cytokine levels (e.g., IFN-γ, IL-6, TNF-α) T-cell receptor (TCR) clonality |
| Other | Metabolic Biomarker Changes in Peripheral Blood and Tumor Tissues | Baseline, during treatment, and at progression (up to 24 months) | Changes in metabolic biomarkers in peripheral blood and tumor tissue samples, including: Serum glucose levels (mg/dL) and insulin resistance markers (e.g., HOMA-IR) Lipid metabolism markers (e.g., triglycerides, total cholesterol, LDL, HDL) Lactate and pyruvate levels as indicators of altered tumor metabolism Amino acid profiling (e.g., glutamine, alanine) for metabolic reprogramming |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers10
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06893380
GET https://conductscience.org/api/trials/v1/NCT06893380/registered